Abstract
Pancreatic ductal adenocarcinoma is a devastating and malignant disease,with a five year survival rate of less than 5％.Despite our improvement of surgical techniques and adjuvant medical therapy,most patients with pancreatic cancer have a dismal prognosis.The poor outcome of this tumor is associated with a high degree of drug resistance.Recently,the emerging knowledge of the molecular basis of pancreatic cancer may provide new avenues to get better prognostication for individual patients based on the molecular profile of obtained tissue by a biopsy or from resected specimens.So some novel drugs targeting signal pathway both within cancer cell and cancer microenvironment are undergoing preclinical.This article reviews the different targeted approaches in pancreatic cancer. Key words: Pancreatic neoplasms ; Molecular targeted therapy ; Tumor microenvironment; Stromal reaction
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
